{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:36:21Z","timestamp":1785321381930,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.jaccao.2019.08.012","type":"journal-article","created":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T13:58:25Z","timestamp":1569333505000},"page":"24-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor"],"prefix":"10.1016","volume":"1","author":[{"given":"Sarah","family":"Waliany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin L.","family":"Sainani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyuan Amy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2019.08.012_bib1","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2019.08.012_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib4","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaccao.2019.08.012_bib5","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib6","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/jhh.2013.30","article-title":"Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis","volume":"27","author":"Funakoshi","year":"2013","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.jaccao.2019.08.012_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib9","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1073\/pnas.1301331110","article-title":"Anti-VEGF\u2013 and anti-VEGF receptor\u2013induced vascular alteration in mouse healthy tissues","volume":"110","author":"Yang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccao.2019.08.012_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0002-9440(10)63273-7","article-title":"Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts","volume":"165","author":"Inai","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.109.129973","article-title":"Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression","volume":"54","author":"Facemire","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.jaccao.2019.08.012_bib12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.jaccao.2019.08.012_bib13","first-page":"72","article-title":"The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients","volume":"1","author":"Hall","year":"2013","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jaccao.2019.08.012_bib14","series-title":"Common toxicity criteria v2.0","year":"1999"},{"key":"10.1016\/j.jaccao.2019.08.012_bib15","series-title":"Common terminology criteria for adverse events v3.0 (CTCAE)","year":"2006"},{"key":"10.1016\/j.jaccao.2019.08.012_bib16","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib17","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2019.08.012_bib18","first-page":"391","article-title":"STRIDE--An integrated standards-based translational research informatics platform","volume":"2009","author":"Lowe","year":"2009","journal-title":"AMIA Annu Symp Proc"},{"key":"10.1016\/j.jaccao.2019.08.012_bib19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004408","article-title":"Longitudinal assessment of vascular function with sunitinib in patients with metastatic renal cell carcinoma","volume":"11","author":"Catino","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jaccao.2019.08.012_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2019.08.012_bib21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib22","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaccao.2019.08.012_bib23","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaccao.2019.08.012_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s11906-999-0016-7","article-title":"Role of nitric oxide in the control of renal function and salt sensitivity","volume":"1","author":"Zou","year":"1999","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jaccao.2019.08.012_bib25","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF Inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2019.08.012_bib26","doi-asserted-by":"crossref","first-page":"14448","DOI":"10.1073\/pnas.0703577104","article-title":"Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions","volume":"104","author":"Advani","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccao.2019.08.012_bib27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-012-2025-5","article-title":"Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis","volume":"71","author":"Qi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib28","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bcp.12149","article-title":"Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis","volume":"76","author":"Qi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jaccao.2019.08.012_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-011-0154-3","article-title":"Development of second-generation VEGFR tyrosine kinase inhibitors: current status","volume":"13","author":"Bhargava","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaccao.2019.08.012_bib30","first-page":"6","article-title":"Hypertension in cancer patients treated with anti-angiogenic based regimens","volume":"1","author":"Wasserstrum","year":"2015","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jaccao.2019.08.012_bib31","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaccao.2019.08.012_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1161\/HYPERTENSIONAHA.112.196774","article-title":"Management of antiangiogenic therapy-induced hypertension","volume":"60","author":"de Jesus-Gonzalez","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jaccao.2019.08.012_bib33","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s10637-010-9549-5","article-title":"Treatment of bevacizumab-induced hypertension by amlodipine","volume":"30","author":"Mir","year":"2012","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaccao.2019.08.012_bib34","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2019.08.012_bib35","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","article-title":"Inhibition of vascular endothelial growth factor-A signaling induces hypertension: examining the effect of cediranib treatment on blood pressure\u00a0in rat and the use of concomitant antihypertensive therapy","volume":"14","author":"Curwen","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087319300341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087319300341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:52:08Z","timestamp":1762973528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087319300341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S2666087319300341"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.012","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2019.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}